Lyell Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-2,754
Closed -$237K 208
2024
Q4
$237K Hold
2,754
0.02% 189
2024
Q3
$328K Hold
2,754
0.03% 174
2024
Q2
$393K Hold
2,754
0.04% 149
2024
Q1
$354K Hold
2,754
0.04% 160
2023
Q4
$285K Buy
2,754
+200
+8% +$19.8K 0.03% 165
2023
Q3
$232K Hold
2,554
0.03% 166
2023
Q2
$207K Hold
2,554
0.03% 176
2023
Q1
$203K Buy
+2,554
New +$181K 0.03% 195

Other funds holding NVO

Lyell Wealth Management's NVO Position: Q1 2025 in Review

Lyell Wealth Management sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 2,754 shares — an estimated $237K sold.

Lyell Wealth Management first reported a position in NVO in Q1 2023 and held it in 8 quarters. The position peaked at $393K in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Lyell Wealth Management reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Lyell Wealth Management sold 2,754 Novo Nordisk shares in Q1 2025, an estimated $237K.
  • Lyell Wealth Management first reported a position in Novo Nordisk in Q1 2023 and held it in 8 quarters.
  • Lyell Wealth Management's Novo Nordisk position peaked at $393K in Q2 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Lyell Wealth Management's 13F filing for Q1 2025, filed 8 May 2025.